

I. **AMENDMENTS TO THE CLAIMS:**

1-10. (Canceled)

11. (Currently Amended) A method of treating psoriasis affected area of the skin, scalp or nails comprising the steps of:

- a) ~~[[Orally]]~~ orally administering to ~~[[the]]~~ a psoriasis affected individual a composition comprising boswellic acid and a selenium compound and ~~, dispersed in a~~ pharmaceutically acceptable carrier; and
- b) topically applying to the ~~[[said]]~~ affected area a composition of boswellic acid and ~~dispersed in a~~ pharmaceutically acceptable carrier.

12. (Currently Amended) ~~The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the orally administered composition contains about 400 mg of boswellic acid represented by one or more of the following groups:

- a) beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as a single entities or mixtures; and
- b) ~~Congeners~~ congeners or derivatives of beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures.

13. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the orally administered composition contains about 100 micrograms of selenium derived from one or more of the following selenium sources: selenomethionine, Selmethylselenocystein, derivatives of selenomethionine, derivatives of Semethylselenocystein, and high selenium yeast.

14. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the topically administered composition contains about 400 mg of boswellic acid represented by one or more of the following groups:

a) beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as a single entities or mixtures; and

b) ~~Congeners~~ congeners or derivatives of beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures.

15. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the orally administered composition contains about 400 mg of acetyl-11-keto-beta-boswellic acid.

16. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the orally administered composition

contains about 100 micrograms of selenium from L(+)-Selenomethionine, ~~in a pharmaceutically acceptable carrier.~~

17. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim claim 11,~~ wherein the topically administered composition contains about 400 mg of acetyl-11-keto-beta-boswellic acid dispersed in a pharmaceutically acceptable carrier.

18. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim claim 11,~~ wherein the total daily oral dose of boswellic acid is about 1200 mg, administered in a plurality of individual doses.

19. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim claim 11,~~ wherein the total daily oral dose of selenium is about 300 micrograms, administered in a plurality of individual doses.

20. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim claim 11,~~ wherein the total daily topical dose of boswellic acid is about 1200 mg, administered in a plurality of individual doses.